Recent clinical data shows the 4CMenB vaccine achieves 32.7 percent effectiveness against gonorrhoea, marking a significant breakthrough in sexually transmitted infection prevention. As the first licensed vaccine demonstrating proven activity against this pathogen, 4CMenB represents a novel therapeutic approach in an era of unprecedented antimicrobial resistance.
This efficacy metric, while moderate, holds substantial public health significance given the current treatment landscape. With 87 percent of gonorrhoea strains in England showing antibiotic resistance, even partial vaccine protection provides meaningful clinical benefit at the population level.
The UK’s rapid adoption of this vaccine in a national programme underscores confidence in the evidence base. Clinical trials have demonstrated varying efficacy depending on bacterial strain and patient demographics, yet consistent protection supports the programme’s expansion to priority populations. International surveillance data will be critical for evaluating real-world effectiveness and informing implementation strategies in other healthcare systems.
Read the full article on GMJ Newsroom.
Was this article helpful?
